1. Home
  2. NXPL vs KTTA Comparison

NXPL vs KTTA Comparison

Compare NXPL & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextPlat Corp

NXPL

NextPlat Corp

N/A

Current Price

$6.36

Market Cap

20.8M

ML Signal

N/A

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.58

Market Cap

23.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXPL
KTTA
Founded
1997
2020
Country
United States
United States
Employees
130
5
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.8M
23.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NXPL
KTTA
Price
$6.36
$0.58
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
24.5K
408.8K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$0.28
52 Week High
$8.37
$2.06

Technical Indicators

Market Signals
Indicator
NXPL
KTTA
Relative Strength Index (RSI) 49.18 32.81
Support Level $0.59 $0.54
Resistance Level $7.19 $0.76
Average True Range (ATR) 0.90 0.05
MACD -0.17 -0.01
Stochastic Oscillator 11.98 23.13

Price Performance

Historical Comparison
NXPL
KTTA

About NXPL NextPlat Corp

NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Share on Social Networks: